(Total Views: 563)
Posted On: 05/18/2024 3:48:34 PM
Post# of 148863
It seems regorafenib is one of the SOC.
Agenus seems to be a competitor in the r/r MSS Crc space. The combination of Botensilimab (Fc enhanced CTLA-4) plus Balstilimab (PD-1) has produced good Phase 1 results:
In the Phase 1 trial of 77 patients with refractory MSS-CRC without active liver metastases, a 23% overall response rate (ORR) was observed after a median follow up of 13.6 months at the data cutoff of March 1, 2024. The estimated 12-month and 18-month OS rates were 71% and 62%, respectively. The median OS was 21.2 months.
They have end of phase 2 meeting with FDA scheduled for July and are anticipating submitting for accelerated approval by end of year.
Their corporate presentation shows how they plan to expand this initial indication across the crc treatment settings.
https://investor.agenusbio.com/files/doc_pres...7-2024.pdf
Agenus seems to be a competitor in the r/r MSS Crc space. The combination of Botensilimab (Fc enhanced CTLA-4) plus Balstilimab (PD-1) has produced good Phase 1 results:
In the Phase 1 trial of 77 patients with refractory MSS-CRC without active liver metastases, a 23% overall response rate (ORR) was observed after a median follow up of 13.6 months at the data cutoff of March 1, 2024. The estimated 12-month and 18-month OS rates were 71% and 62%, respectively. The median OS was 21.2 months.
They have end of phase 2 meeting with FDA scheduled for July and are anticipating submitting for accelerated approval by end of year.
Their corporate presentation shows how they plan to expand this initial indication across the crc treatment settings.
https://investor.agenusbio.com/files/doc_pres...7-2024.pdf
(5)
(0)Scroll down for more posts ▼
